Comparative Pharmacology
Head-to-head clinical analysis: NEXTERONE versus PRONESTYL SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXTERONE versus PRONESTYL SR.
NEXTERONE vs PRONESTYL-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration by blocking potassium channels (IKr), primarily affecting the atria and ventricles.
Class Ia antiarrhythmic agent; blocks sodium channels, slowing phase 0 depolarization and decreasing myocardial excitability; also prolongs refractory period and has anticholinergic effects.
Intravenous loading: 150 mg over 10 minutes, then 1 mg/min for 6 hours, followed by maintenance infusion of 0.5 mg/min. Oral: 400 mg twice daily for loading (total 1200 mg/day) for 7-10 days, then maintenance 200-400 mg once daily.
500–1000 mg orally every 6 hours (sustained-release). Maximum 1.5 g per dose or 4 g per day.
None Documented
None Documented
Terminal elimination half-life of 58 days (range 25-110 days) due to extensive tissue distribution and slow release from lipid stores. Steady-state concentrations require approximately 3-6 months of chronic dosing.
2.5-4.7 hours (procainamide); 6-9 hours (NAPA, active metabolite). Prolonged in renal impairment (up to 11-20 hours for procainamide, 30-42 hours for NAPA).
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary excretion of metabolites is significant, with approximately 30-40% eliminated in feces. Renal excretion accounts for ~15-20% of total clearance as metabolites.
Renal excretion: ~50-60% unchanged drug (procainamide), ~15-30% as N-acetylprocainamide (NAPA). Biliary/fecal: minor (<5%).
Category C
Category C
Antiarrhythmic
Antiarrhythmic